Ajay Dhakal
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Background Leptomeningeal disease (LMD) is a serious complication of metastatic breast cancer (MBC) with poor survival. This single-institution retrospective study compares overall survival (OS) among MBC patients with LMD based on CSF parameters (glucose, protein, and WBC count) Methodology MBC patients who were diagnosed with LMD between 2010-2023 at Wilmot Cancer Institute were screened for eligibility. Only those with available data on CSF glucose, protein, and WBC count were included. OS was assessed via the Kaplan-Meier method and compared using the log-rank test. Cox models were used for multivariate analysis. Results Out of 69 patients with MBC LMD, 28 had CSF data and were included in the final analysis. The CSF cytology-positive cohort had significantly lower glucose levels vs the CSF cytology-negative cohort [median (IQR) 40 (18-58) vs 64 (53-92) mg/dl, p=0.006]. Median CSF WBC count was significantly higher in the CSF cytology positive cohort vs the CSF cytology negative cohort [median (IQR) 13 (6-44) vs. 2(2-4)cells/mm 3 , p=0.001]. When stratified by CSF cytology results and CSF glucose levels, the CSF cytology negative, glucose-low group was associated with the worst OS, while the CSF cytology negative, normal/high glucose group was associated with the best OS( p =0.03) in an unadjusted analysis. Multivariate analysis confirmed that low CSF glucose was independently associated with poorer survival [HR 4.64 (1.71, 13.2)]. Neither CSF protein levels nor CSF WBC counts were significantly associated with OS in unadjusted and multivariate analyses. Conclusion Low CSF glucose was associated with worse OS than normal/high CSF glucose. There was insufficient evidence to suggest that CSF protein or CSF WBC counts were associated with OS.
Year:
2026
Year:
2025
Year:
2025
Background. Breast cancer has an unacceptably high recurrence rate when any residual disease is found following neoadjuvant treatment of high-risk disease. Based on clinical data suggesting an adjuvant role for epigenetic modifying agents in breast cancer and preclinical data suggesting synergistic activity of entinostat combined with capecitabine, we conducted a phase I, open-label study of these agents in metastatic breast cancer (MBC). Both agents have published doses for use in combination therapy, but the agents had not previously been combined with each other in a human trial. Methods. A multisite phase I dose escalation study was performed at two academic centers. Patients with pretreated, HER2-negative MBC, and measurable disease were enrolled. Dual dose escalation was performed via a Bayesian partial order continual assessment method. Dose levels ranged from entinostat 3 mg to 5 mg and capecitabine 800 mg/m2 to 1000 mg/m2. Results. Thirteen patients with MBC and a median of 4 lines of prior therapy were enrolled across four dose level combinations. The most common toxicities were neutropenia, thrombocytopenia, and palmar-plantar dysesthesia, which were expected toxicities. No new safety signals were observed. One dose-limiting toxicity was observed, which did not exceed a prespecified toxicity rate of 25%. The median treatment duration was 2.37 months. No partial nor complete responses were observed. The study was halted early prior to entering an expansion phase, due to drug supply limitations. Conclusion. The tested dosing combinations of entinostat and capecitabine are likely safe in heavily pretreated metastatic breast cancer. This study’s clinical investigation of entinostat in breast cancer was halted, but drug development of this agent continues outside the US. There remains a need for postoperative adjuvant drug therapy for the subpopulation of breast cancer patients with high-risk residual cancer after curative therapy. This trial is registered with NCT03473639.
Year:
2024
Breast augmentation is considered safe, but rare cases of breast implant-associated squamous cell carcinoma (BIA-SCC) have been reported. This study aimed to systematically review published cases of BIA-SCC, providing valuable clinical data. The review included 14 articles and 18 cases of BIA-SCC. An increasing trend in reported BIA-SCC cases was observed, with four cases in the 1990s and 14 cases since 2010. The mean age of affected patients was 56 years, and symptoms typically appeared around 21 years after breast augmentation. Silicone implants used in cosmetic procedures were most commonly associated with BIA-SCC. Implant removal was necessary in all cases, and some patients required a mastectomy. Treatment approaches varied, with the selective use of chemotherapy and/or radiotherapy. The estimated 6-month mortality rate was 11.1%, while the 12-month mortality rate was 23.8%. The estimated 6-month mortality rate should be cautiously interpreted due to the limited sample size. It appears lower than the rate reported by the American Society of Plastic Surgeons, without clear reasons for this discrepancy. This study highlights the importance of enhanced monitoring and information sharing to improve detection and management of BIA-SCC. Healthcare providers should maintain vigilance during the long-term follow-up of breast augmentation patients.
Year:
2023
Collaborators (2)
Carey Anders
Assistant Director of Clinical Research
Duke University
Patrick Dillon
Assistant Professor
University of Virginia
Make your next move.
Prepare your application
Review drafts before you send them.